Okumichi H, et al. – A prospective study is carried out to assess the ocular–surface safety of a 0.001% benzalkonium chloride–containing tafluprost/timolol fixed combination (TTFC) in patients with primary open–angle glaucoma (POAG) or ocular hypertension who have inadequate intraocular pressure (IOP) control with latanoprost monotherapy. Based on these outcomes, the ocular–surface safety of TTFC is not significantly different to that of latanoprost. Furthermore, switching from latanoprost to TTFC in patients with insufficient IOP control has additive IOP–lowering impacts. TTFC is an effective approach for patients receiving latanoprost monotherapy who require more intensive IOP reduction.